Eptifibatide

DEA Class; Rx

Common Brand Names; Integrilin

• Antiplatelet Agents, Cardiovascular; 
• Glycoprotein IIb/IIIa Inhibitors

Hypersensitivity

History of internal bleeding, intracranial hemorrhage or neoplasm, CVA, thrombocytopenia

AV malformation or aneurysm, aortic dissection, severe HTN, acute pericarditis

Other parenteral glycoprotein IIb/IIIa inhibitors

• Bleeding (8%)
• Hypotension (7%)
• Thrombocytopenia (2.3%)
• Injection site reaction
• Hypersensitivity
• Intracranial hemorrhage
• Pulmonary hemorrhage
• Thrombocytopenia
• GI hemorrhage
• Immune-mediated thrombocytopenia (thought to be caused by antibodies that react with GP IIb/IIIa complex)

—

Available data on use in pregnant women from published literature and pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

Untreated myocardial infarction can be fatal to pregnant woman and fetus

There are no available data on presence of drug in human milk, effects on breastfed infant, or on milk production; as drug is a peptide, it is likely to be destroyed in infant’s gastrointestinal tract and not absorbed orally by the breastfed infant